Skip to main content
SpringerLink
Log in

Borderline-Tumoren des Ovars

Borderline ovarian tumors

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Borderline Tumoren des Ovars (BOT) stehen klinisch wie morphologisch zwischen den zelltypspezifischen benignen und malignen Ovartumoren. Die Hypothese einer kontinuierlichen Karzinogenese wurde anhand eines Modells zur Genese maligner Ovarialtumoren theoretisch unterstützt. Seine Übertragbarkeit auf die verschiedenen Ovarialmalignomentitäten ist noch nicht abschließend geklärt, dennoch hat das Modell auch relevante Implikationen für das Management von BOT. Betroffen von BOT sind überproportional häufig Frauen im reproduktiven Alter, sodass sich bei der Therapie grundsätzlich die Frage nach einem Fertilitätserhalt stellt. Neben Alter und FIGO-Stadium scheint die Zytoreduktion durch die Primäroperation das entscheidende prognostische Kriterium zu sein, der postoperativ verbliebene Tumorrest ist ein unabhängiger Prognosefaktor. Neben diesen Aspekten wird der Stand in den Bereichen Therapie der BOT und Prognose referiert.

Abstract

Borderline ovarian tumors (BOT) are clinically and morphologically defined as being between cell-specific benign and malignant ovarian tumors. The hypothesis of a continuous carcinogenesis is theoretically supported by a model of the genesis of malignant ovarian tumors. The transferability to various ovarian malignancies has not yet been finally explained but the model also has relevant implications for the management of BOT. Women in child-bearing age are disproportionally more often affected by BOT so that the question of therapy is basically concerned with maintaining fertility. In addition to age and FIGO stage, cytoreduction by the primary operation seems to be the deciding prognostic factor and the residual postoperative tumor mass is an independent prognosis factor. In addition to these aspects the current situation with respect to BOT and prognosis will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Behtash N, Modares M, Abolhasani M et al (2004) Borderline ovarian tumours: clinical analysis of 38 cases. J Obstet Gynaecol 24:157–160

    Article  PubMed  CAS  Google Scholar 

  2. Berretta R, Rolla M, Patrelli TS et al (2009) Incidence of port-site metastasis after laparoscopic management of borderline ovarian tumors: a series of 22 patients. Eur J Gynaecol Oncol 30:300–302

    PubMed  CAS  Google Scholar 

  3. Cadron I, Leunen K, Van Gorp T et al (2007) Management of borderline ovarian neoplasms. J Clin Oncol 25:2928–2937

    Article  PubMed  Google Scholar 

  4. Camatte S, Morice P, Thoury A et al (2004) Impact of surgical staging in patients with macroscopic „stage I“ ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 40:1842–1849

    Article  PubMed  Google Scholar 

  5. Cetin I, Cozzi V, Antonazzo P (2008) Infertility as a cancer risk factor – a review. Placenta 29 (Suppl B):169–177

    Article  PubMed  Google Scholar 

  6. Chang SJ, Ryu HS, Chang KH et al (2008) Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand 87:476–481

    Article  PubMed  Google Scholar 

  7. Crispens MA (2003) Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 15:39–43

    Article  PubMed  Google Scholar 

  8. Cusido M, Balaguero L, Hernandez G et al (2007) Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 104:617–622

    Article  PubMed  Google Scholar 

  9. Donnez J, Munschke A, Berliere M et al (2003) Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 79:1216–1221

    Article  PubMed  Google Scholar 

  10. Bois A du, Emons G et al (Hrsg) (2007) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren 2007. Schmalfeldt B, Pfisterer J, W. Zuckschwerdt, München

  11. Bois A du, Ewald-Riegler N, Bois O du, Harter P (2009) Borderline-Tumoren des Ovars – eine systematische Übersicht. Geburtshilfe Frauenheilkd 69:807–833

    Article  Google Scholar 

  12. Fauvet R, Boccara J, Dufournet C et al (2005) Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 16:403–410

    Article  PubMed  CAS  Google Scholar 

  13. Fortin A, Morice P, Thoury A et al (2007) Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 87:591–596

    Article  PubMed  Google Scholar 

  14. Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16:513–527

    Article  PubMed  Google Scholar 

  15. Gram IT, Braaten T, Adami HO et al (2008) Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer 122:647–652

    Article  PubMed  CAS  Google Scholar 

  16. Jones MB (2006) Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 49:517–525

    Article  PubMed  Google Scholar 

  17. Jordan SJ, Green AC, Whiteman DC, Webb PM (2007) Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol 107:223–230

    Article  PubMed  Google Scholar 

  18. Kokawa K, Mikami Y, Sakata H et al (2009) Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years‘ experience in the Kinki District of Japan (1990–2006). Eur J Gynaecol Oncol 30:155–161

    PubMed  CAS  Google Scholar 

  19. Kommoss GBF (2002) Borderline-Tumoren des Ovars. Onkologie 8:1149–1159

    Article  Google Scholar 

  20. Koskas M, Uzan C, Gouy S et al (2011) Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 18:40–48

    Article  PubMed  Google Scholar 

  21. Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160

    PubMed  Google Scholar 

  22. Kurman RJ, Visvanathan K, Roden R et al (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351–356

    Article  PubMed  Google Scholar 

  23. Ortiz BH, Ailawadi M, Colitti C et al (2001) Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61:7264–7267

    PubMed  CAS  Google Scholar 

  24. Parazzini F, Negri E, La Vecchia C et al (1998) Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 68:226–228

    Article  PubMed  CAS  Google Scholar 

  25. Scully R (1999) World Health Organization International classification of tumours. Histological typing of ovarian tumors, 2nd edn. Springer, Berlin Heidelberg New York Tokyo

  26. Shih KK, Garg K, Soslow RA et al (2011) Accuracy of frozen section diagnosis of ovarian borderline tumor. Gynecol Oncol 123:517–521

    Article  PubMed  CAS  Google Scholar 

  27. Silva EG, Gershenson DM, Malpica A, Deavers M (2006) The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 30:1367–1371

    Article  PubMed  Google Scholar 

  28. Stelmachow J, Timorek-Lemieszczuk A (2008) Technetium-99 m-sestamibi scintigraphy in gynecological cancer imaging. Eur J Gynaecol Oncol 29:309–312

    PubMed  CAS  Google Scholar 

  29. Taylor HJ (1929) Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 48:204–230

    Google Scholar 

  30. Wang X, Wang RH, Li W et al (2004) Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure. J Biol Chem 279:29606–29614

    Article  PubMed  CAS  Google Scholar 

  31. Webb PM, Purdie DM, Grover S et al (2004) Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 92:232–239

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin erklärt für sich und ihre Koautoren, dass kein Interessenkonflikt vorliegt.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Haus 24, 24105, Kiel, Deutschland

    A. Wenners, M. Bauer, A. Strauss & F. Hilpert

Authors
  1. A. Wenners
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Hilpert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Wenners.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wenners, A., Bauer, M., Strauss, A. et al. Borderline-Tumoren des Ovars. Gynäkologe 45, 296–303 (2012). https://doi.org/10.1007/s00129-012-2959-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-012-2959-z

Schlüsselwörter

Keywords

Search

Navigation